Literature DB >> 32886201

Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Se Jin Cho1, Yun Jung Bae2, Jong-Min Kim3, Donghyun Kim4, Sung Hyun Baik1, Leonard Sunwoo1, Byung Se Choi1, Jae Hyoung Kim1.   

Abstract

OBJECTIVE: To determine the diagnostic performance of neuromelanin-sensitive magnetic resonance imaging discriminating between patients with Parkinson's disease and normal healthy controls and to identify factors causing heterogeneity influencing the diagnostic performance.
METHODS: A systematic literature search in the Ovid-MEDLINE and EMBASE databases was performed for studies reporting the relevant topic before February 17, 2020. The pooled sensitivity and specificity values with their 95% confidence intervals were calculated using bivariate random-effects modeling. Subgroup and meta-regression analyses were also performed to determine factors influencing heterogeneity.
RESULTS: Twelve articles including 403 patients with Parkinson's disease and 298 control participants were included in this systematic review and meta-analysis. Neuromelanin-sensitive magnetic resonance imaging showed a pooled sensitivity of 89% (95% confidence interval, 86-92%) and a pooled specificity of 83% (95% confidence interval, 76-88%). In the subgroup and meta-regression analysis, a disease duration longer than 5 and 10 years, comparisons using measured volumes instead of signal intensities, a slice thickness in terms of magnetic resonance imaging parameters of more than 2 mm, and semi-/automated segmentation methods instead of manual segmentation improved the diagnostic performance.
CONCLUSION: Neuromelanin-sensitive magnetic resonance imaging had a favorable diagnostic performance in discriminating patients with Parkinson's disease from healthy controls. To improve diagnostic accuracy, further investigations directly comparing these heterogeneity-affecting factors and optimizing these parameters are necessary. KEY POINTS: • Neuromelanin-sensitive MRI favorably discriminates patients with Parkinson's disease from healthy controls. • Disease duration, parameters used for comparison, magnetic resonance imaging slice thickness, and segmentation methods affected heterogeneity across the studies.

Entities:  

Keywords:  Magnetic resonance imaging; Neuromelanin; Parkinson disease

Mesh:

Substances:

Year:  2020        PMID: 32886201     DOI: 10.1007/s00330-020-07240-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  48 in total

1.  Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.

Authors:  Makoto Sasaki; Eri Shibata; Koujiro Tohyama; Junko Takahashi; Kotaro Otsuka; Kuniaki Tsuchiya; Satoshi Takahashi; Shigeru Ehara; Yasuo Terayama; Akio Sakai
Journal:  Neuroreport       Date:  2006-07-31       Impact factor: 1.837

Review 2.  Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.

Authors:  H Fedorow; F Tribl; G Halliday; M Gerlach; P Riederer; K L Double
Journal:  Prog Neurobiol       Date:  2005-02       Impact factor: 11.685

3.  Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.

Authors:  Gabriel Castellanos; María A Fernández-Seara; Oswaldo Lorenzo-Betancor; Sara Ortega-Cubero; Marc Puigvert; Javier Uranga; Marta Vidorreta; Jaione Irigoyen; Elena Lorenzo; Arrate Muñoz-Barrutia; Carlos Ortiz-de-Solorzano; Pau Pastor; María A Pastor
Journal:  Mov Disord       Date:  2015-03-15       Impact factor: 10.338

4.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

5.  3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.

Authors:  Kimihiro Ogisu; Kohsuke Kudo; Makoto Sasaki; Ken Sakushima; Ichiro Yabe; Hidenao Sasaki; Satoshi Terae; Mitsuhiro Nakanishi; Hiroki Shirato
Journal:  Neuroradiology       Date:  2013-03-23       Impact factor: 2.804

6.  Pathological basis for neurotransmitter changes in Parkinson's disease.

Authors:  D M Mann; P O Yates
Journal:  Neuropathol Appl Neurobiol       Date:  1983 Jan-Feb       Impact factor: 8.090

7.  Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.

Authors:  Margherita Fabbri; Sofia Reimão; Miguel Carvalho; Rita G Nunes; Daisy Abreu; Leonor Correia Guedes; Raquel Bouça; Patricia P Lobo; Catarina Godinho; Miguel Coelho; Nilza C Gonçalves; Mario Miguel Rosa; Angelo Antonini; Joaquim J Ferreira
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

8.  Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease.

Authors:  Ioannis U Isaias; Paula Trujillo; Paul Summers; Giorgio Marotta; Luca Mainardi; Gianni Pezzoli; Luigi Zecca; Antonella Costa
Journal:  Front Aging Neurosci       Date:  2016-08-22       Impact factor: 5.750

9.  Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin.

Authors:  Ken Nakamura; Keizo Sugaya
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

10.  Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.

Authors:  Hiroshi Kawaguchi; Hitoshi Shimada; Fumitoshi Kodaka; Masayuki Suzuki; Hitoshi Shinotoh; Shigeki Hirano; Jeff Kershaw; Yuichi Inoue; Masaki Nakamura; Taeko Sasai; Mina Kobayashi; Tetsuya Suhara; Hiroshi Ito
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

View more
  4 in total

1.  Acceleration of neuromelanin-sensitive MRI sequences in the substantia nigra using standard MRI options.

Authors:  Marieke van der Pluijm; Elon D Wallert; Bram F Coolen; Kaithlyn T Tjong Tjin Joe; Lieuwe de Haan; Jan Booij; Elsmarieke van de Giessen
Journal:  Neuroradiology       Date:  2022-09-28       Impact factor: 2.995

2.  Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders.

Authors:  Elon D Wallert; Elsmarieke van de Giessen; Remco J J Knol; Martijn Beudel; Rob M A de Bie; Jan Booij
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

Review 3.  Magnetic resonance imaging of the dopamine system in schizophrenia - A scoping review.

Authors:  Julia Schulz; Juliana Zimmermann; Christian Sorg; Aurore Menegaux; Felix Brandl
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

Review 4.  [MRI Findings in Parkinson's Disease: Radiologic Assessment of Nigrostriatal Degeneration].

Authors:  Yun Jung Bae; Jong-Min Kim; Byung Se Choi; Yoo Sung Song; Yoonho Nam; Se Jin Cho; Jae Hyoung Kim; Sang Eun Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.